Design the model you need
- Heart
- Liver
- Brain
- Pancreas
- Kidney
- Intestine
- Isolated primary cells
- Cell lines
- iPSCs
- Adult stem cells
- Adult patient samples
- Pediatric patient samples
- Matrigel
- Human polysynthetic hydrogels
- Matrix-free (suspension)
- 3D spheroids
- 3D organoids derived from iPSCs
- 3D organoids derived from patients (PDOs)
- 3D tumoroids
- 2D cell culture
- 2D/3D Co-Culture
- Organ-specific morphology
- Organ-specific functionality
- Organ-/Disease-specific marker expression
- All types of well plates
- Organ-on-a-chip
- Petri dish
- Oncology
- Developmental disorders
- Genetic disorders
- Infectious diseases
- Toxicology and safety testing
- Drug screening
- Disease modeling
Explore real-world applications
Drug discovery
3D cell culture models have redefined how pharmacological and toxicological assays are designed, offering improved predictive power and reproducibility compared with 2D cultures.
These platforms support high-throughput testing of compound libraries, providing more realistic responses to drug toxicity, efficacy, and metabolism.
A recent case that exemplifies organoid potential in drug discovery is the development of the bispecific antibody MCLA-158. From a library of more than 500 bispecific antibodies, functional screening across colorectal cancer organoids identified MCLA-158 as the most selective candidate. The entire discovery program relied exclusively on patient-derived colorectal cancer organoid lines, enabling direct assessment of tumor-specific responses. The program advanced from discovery to phase I trials in 30 months. Ongoing clinical trials include phase III studies in head and neck squamous cell carcinoma (NCT06496178).
Herpers, B., Eppink, B., James, M.I. et al. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nat Cancer 3, 418–436 (2022).
Disease modeling
3D organoid cultures reproduce the architecture, function, and cellular diversity of human tissues, allowing direct observation of human-specific mechanisms.
Some examples include:
- Genetic and metabolic disorders
Organoids derived from patients or engineered lines enable functional studies under physiological conditions, predicting responses in cystic fibrosis and modeling diseases such as α1-antitrypsin deficiency, Wilson’s disease, and polycystic kidney disease. - Neurological and infectious diseases
Brain organoids uncover mechanisms of neurodevelopmental and degenerative disorders like Parkinson’s and Alzheimer’s, and model viral infections including Zika and SARS-CoV-2, complemented by intestinal and airway organoids for immune and replication studies. - Oncology Patient-derived tumor organoids preserve primary tumor histology and mutations, supporting personalized drug testing, biomarker discovery, and assessment of immune checkpoint inhibitors through immune-enhanced co-cultures.
- Genetic and metabolic disorders
MO:RE has verified assays of FDA NAM Roadmap
| FDA assay | MO:RE capabilities | Status | |
|---|---|---|---|
|
Liver toxicity |
Liver organoid culture; compound dosing; real-time
QC (morphology) |
|
|
|
Cardiac toxicity |
Cardiac organoid culture; compound dosing; time-series QC |
|
|
|
Barrier integrity (GI, CNS) |
Brain organoid culture with apical/basal polarity; compatible with permeability assays; add intestinal organoids |
|
|
|
Cytokine release / Immune effects |
Cytokine release assay with synovial organoids (patient derived) |
|
|
|
Kidney toxicity |
Kidney organoid culture; compound dosing |
|
|
|
Mechanism-of-action |
Target engagement + morphology readouts in 3D tissue context; sample prep for phenotype readout |
|
|
Yes